Actinium Pharmaceuticals
ATNM
40 hedge funds and large institutions have $5.8M invested in Actinium Pharmaceuticals in 2019 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 8 increasing their positions, 5 reducing their positions, and 7 closing their positions.
60% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 5
0% more capital invested
Capital invested by funds: $5.78M → $5.8M (+$15K)
0.03% more ownership
Funds ownership: 0.48% → 0.52% (+0.03%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
9% less funds holding
Funds holding: 44 → 40 (-4)
57% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$376K |
| 2 |
SCM
Sio Capital Management
New York
|
+$248K |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
+$105K |
| 4 |
Renaissance Technologies
New York
|
+$67K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$35.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ECM
Endurant Capital Management
San Mateo,
California
|
-$262K |
| 2 |
FI
Fosun International
Hong Kong,
China
|
-$147K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$13.7K |
| 4 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$13K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$8K |
ATNM Hedge Fund Activity: Q3 2019 in Review
40 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Actinium Pharmaceuticals (ATNM) for Q3 2019, worth a combined $5.8M — up 0.26% from $5.78M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of ATNM and 3 opened new positions — a net loss of 4 holders — while 5 trimmed existing stakes and 8 added.
The largest buyer was Vanguard Group, adding an estimated $376K. The largest seller was Endurant Capital Management, cutting an estimated $262K.
- 40 institutional investors held Actinium Pharmaceuticals (ATNM) as of Q3 2019, down from 44 in Q2 2019.
- Funds reported $5.8M of Actinium Pharmaceuticals stock for Q3 2019, up 0.26% quarter-over-quarter.
- 3 funds opened new Actinium Pharmaceuticals positions in Q3 2019 and 7 closed out, a net change of -4 holders.
- The largest Actinium Pharmaceuticals buyer in Q3 2019 was Vanguard Group, an estimated $376K added.
- The largest Actinium Pharmaceuticals seller in Q3 2019 was Endurant Capital Management, an estimated $262K sold.
Based on aggregated 13F filings for Q3 2019.